GT Biopharma financials
$6.88+1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M |
| Net income | -$34.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-167.00 | $-173.50 | $-141.00 | $-491.50 | $-1545.00 |
| EBITDA | -$12.4M | -$14.4M | -$13.6M | -$21.2M | -$57.5M |
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M |
| Free cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | — |
| Diluted shares | 0.2M | 0.1M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M |
| Short-term investments | $0.00 | $0.00 | $12.9M | $10.8M | $23.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $31.0K |
| Total assets | $8.1M | $4.2M | $14.1M | $16.7M | $32.2M |
| Total liabilities | $2.3M | $5.9M | $6.6M | $5.0M | $10.3M |
| Shareholders' equity | $5.8M | -$1.7M | $7.5M | $11.7M | $21.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology